3 April 2023 ORYZON announces positive results from planned interim analysis of PORTICO, a Phase 2b adaptive trial in Borderline Personality Disorder
15 March 2023 ORYZON announces First Patient In in FRIDA, a Phase Ib trial with iadademstat in relapsed/refractory FLT3-mutant acute myeloid leukemia patients
13 March 2023 ORYZON announces clinical candidate nomination of ORY-4001 for the treatment of CNS disorders
22 February 2023 ORYZON Hosting Key Opinion Leader Webinar on Targeting Lysine Specific Demethylase 1 (LSD1) in CNS and Psychiatric Disorders and Oncology
17 February 2023 ORYZON reports financial results and corporate update for quarter ended December 31, 2022
18 January 2023 ORYZON announces First Patient In in NET, a collaborative Phase II basket study with iadademstat in R/R patients with neuroendocrine carcinomas
16 December 2022 ORYZON awarded EU grant to further explore the role of iadademstat in oncological immunotherapy approaches
12 December 2022 ORYZON presents final data from Phase IIa ALICE trial in unfit AML patients with first-line treatment of iadademstat and azacitidine in oral presentation at ASH-2022